New York State Common Retirement Fund Increases Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

New York State Common Retirement Fund lifted its position in shares of Apogee Therapeutics, Inc. (NASDAQ:APGE) by 8.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,187 shares of the company’s stock after buying an additional 1,000 shares during the quarter. New York State Common Retirement Fund’s holdings in Apogee Therapeutics were worth $552,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the company. Point72 Asset Management L.P. lifted its position in shares of Apogee Therapeutics by 162.7% in the third quarter. Point72 Asset Management L.P. now owns 707,268 shares of the company’s stock valued at $41,545,000 after acquiring an additional 438,036 shares in the last quarter. Geode Capital Management LLC raised its stake in Apogee Therapeutics by 11.2% during the 3rd quarter. Geode Capital Management LLC now owns 823,839 shares of the company’s stock valued at $48,401,000 after purchasing an additional 82,978 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Apogee Therapeutics by 17.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 280,428 shares of the company’s stock worth $16,472,000 after purchasing an additional 41,686 shares in the last quarter. Vestal Point Capital LP bought a new position in Apogee Therapeutics in the 3rd quarter worth approximately $8,018,000. Finally, Victory Capital Management Inc. grew its holdings in Apogee Therapeutics by 121.6% during the 3rd quarter. Victory Capital Management Inc. now owns 346,358 shares of the company’s stock valued at $20,345,000 after buying an additional 190,092 shares in the last quarter. Institutional investors own 79.04% of the company’s stock.

Insiders Place Their Bets

In related news, insider Carl Dambkowski sold 3,520 shares of the firm’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $40.69, for a total transaction of $143,228.80. Following the completion of the sale, the insider now directly owns 252,623 shares of the company’s stock, valued at approximately $10,279,229.87. This trade represents a 1.37 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Mark C. Mckenna acquired 20,000 shares of the company’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $49.54 per share, with a total value of $990,800.00. Following the acquisition, the director now owns 20,000 shares in the company, valued at $990,800. This trade represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders sold a total of 42,145 shares of company stock valued at $1,897,799 over the last 90 days. Insiders own 36.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on APGE shares. Wedbush reissued an “outperform” rating and issued a $90.00 target price on shares of Apogee Therapeutics in a report on Monday. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a report on Monday, November 25th. They set a “buy” rating and a $89.00 price objective for the company. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 target price on the stock. Finally, Guggenheim reiterated a “buy” rating on shares of Apogee Therapeutics in a research report on Monday, February 10th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Apogee Therapeutics currently has a consensus rating of “Buy” and an average price target of $89.71.

Apogee Therapeutics Stock Performance

NASDAQ:APGE opened at $30.37 on Wednesday. The firm has a market capitalization of $1.37 billion, a PE ratio of -12.55 and a beta of 2.46. The stock’s fifty day moving average is $40.01 and its 200 day moving average is $47.32. Apogee Therapeutics, Inc. has a fifty-two week low of $29.10 and a fifty-two week high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last announced its earnings results on Monday, March 3rd. The company reported ($1.19) earnings per share for the quarter, missing the consensus estimate of ($0.94) by ($0.25). Equities analysts forecast that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.